Daily Pharma News - 9 October 2026

NPPA Proposes 30% Trade Margin Cap on Non-Scheduled Cancer Drugs — MRPs May Fall 20-70%

At its 151st meeting on 8 October 2026, chaired by Department of Pharmaceuticals Secretary Manoj Joshi, the National Pharmaceutical Pricing Authority (NPPA) gave in-principle approval to Trade Margin Rationalisation for non-scheduled anti-cancer medicines under Paragraph 19 of the Drugs (Prices Control) Order, 2013. The proposal caps the trade margin — the gap between the price at which a drug is sold to the distributor and its maximum retail price (MRP) — at 30% of the MRP.

NPPA data shows average trade mark-ups of around 170% on cancer drugs, reaching up to 700% in some cases. Rationalising margins to 30% is expected to cut MRPs by 20-70% and save Indian patients roughly Rs 2,500 crore every year. An expert committee will finalise the list of drugs covered by the measure by 14 October. For pharmacy students, this is a live case study in drug price regulation under DPCO 2013: it shows how the NPPA uses its Paragraph 19 powers beyond the scheduled-drug ceiling-price mechanism, and how trade margin rationalisation works as an alternative to direct price capping.

Supreme Court Directs Centre to Form Expert Panel Against Unethical Pharma Marketing

A Supreme Court bench of Justices Vikram Nath and Sandeep Mehta directed the Union government on 8 October to constitute an expert committee within two weeks to examine unethical marketing practices by pharmaceutical companies — including gifts and benefits offered to doctors — and to recommend statutory safeguards. The Centre has been asked to file a compliance affidavit, with the next hearing scheduled for 29 January.

The direction puts the spotlight on enforcement of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, whose effectiveness the court questioned. For pharmacy students, the case connects directly to pharmaceutical marketing ethics, the doctor-pharma relationship, and the limits of voluntary industry codes — themes that appear regularly in regulatory affairs and pharmacy jurisprudence examinations.

Fake Antibiotics Racket Busted: 15,000 Counterfeit Vials Sold Across India, Karnataka SIT Reveals

A Special Investigation Team of the Karnataka Police revealed on 8 October that an interstate racket sold approximately 15,000 vials of fake antibiotic injections over 18 months. Labels of Pfizer's Zavicefta and Emblavco were imported from Turkey and pasted onto substandard or expired vials, which were then sold in Bengaluru, Chennai and Delhi, generating sales of around Rs 10 crore. The alleged ringleader, Prashanth Rajan Babu, has been arrested.

The case is a textbook example of drug counterfeiting and the dangers of spurious medicines under the Drugs and Cosmetics Act, 1940. For pharmacy students, it underlines the importance of supply-chain vigilance, batch verification, and adverse event reporting — and shows how counterfeiters exploit the brand value of high-end antibiotics. Zavicefta (ceftazidime-avibactam) is a reserve antibiotic for resistant Gram-negative infections, which makes the falsification especially dangerous for antimicrobial resistance management in India.

China NMPA Approves Enhertu (Fam-Trastuzumab Deruxtecan) as Adjuvant Therapy for HER2-Positive Early Breast Cancer

China's National Medical Products Administration (NMPA) approved fam-trastuzumab deruxtecan — marketed as Enhertu (T-DXd) — on 8 October for the adjuvant treatment of HER2-positive early breast cancer with residual invasive disease after neoadjuvant taxane and trastuzumab therapy. The approval rests on the DESTINY-Breast05 trial, which showed a 53% lower risk of recurrence or death versus trastuzumab emtansine (T-DM1), with a hazard ratio of 0.47 and three-year invasive disease-free survival of 92.4%.

Enhertu is an antibody-drug conjugate (ADC) — a monoclonal antibody linked to a cytotoxic payload — and this approval extends its use into earlier treatment settings. Interstitial lung disease (ILD) remains the key safety concern, making patient monitoring and adverse drug reaction reporting essential. For Indian pharmacy students, ADCs are among the most important trends in targeted oncology pharmacology, and understanding how T-DXd differs from T-DM1 in payload and linker chemistry is directly exam-relevant.

FDA Approves Atezolizumab (Tecentriq) Plus Chemotherapy as Adjuvant for Stage III dMMR Colon Cancer

The US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, including the subcutaneous Hybreza formulation) on 8 October, in combination with fluoropyrimidine and oxaliplatin chemotherapy, as adjuvant treatment for adults and children aged two years and above with Stage III mismatch repair-deficient (dMMR) colon cancer. In the ATOMIC trial of 712 patients, the combination halved the risk of disease recurrence, with a disease-free survival hazard ratio of 0.50 compared with chemotherapy alone.

Atezolizumab is a PD-L1 immune checkpoint inhibitor, and this approval brings immunotherapy into the adjuvant setting for a biomarker-defined colon cancer population. Immune-mediated adverse reactions feature prominently in the warnings — a reminder of why pharmacovigilance matters as checkpoint inhibitors move earlier in treatment. The paediatric inclusion, from age two, is also notable, since oncology approvals rarely extend to children this young.

FDA Approves Tucatinib (Tukysa) Maintenance for HER2-Positive Metastatic Breast Cancer

On 7 October, the FDA approved tucatinib (Tukysa) in combination with trastuzumab and pertuzumab as maintenance therapy for HER2-positive unresectable or metastatic breast cancer following induction treatment. The HER2CLIMB-05 trial, with 654 patients, reported median progression-free survival of 24.9 months versus 16.3 months in the control arm — a hazard ratio of 0.64. The approval carries a boxed warning for hepatotoxicity.

Tucatinib is a highly selective HER2 tyrosine kinase inhibitor, and pairing it with two HER2-directed antibodies represents an aggressive triple-blockade strategy. Notably, this FDA action lands in the same week as China's adjuvant Enhertu approval — HER2-targeted oncology is advancing on two fronts at once, from early to metastatic disease. For students, the boxed warning is a clear signal to study drug-induced liver injury and the monitoring protocols required for tyrosine kinase inhibitors.

Russia Registers Elefusa (Fuzuloparib), a New PARP Inhibitor for Ovarian and BRCA-Mutated Breast Cancer

Russia's Ministry of Health has registered Elefusa (fuzuloparib), an original domestically developed drug, for maintenance therapy of platinum-responsive advanced ovarian, fallopian tube and peritoneal cancers, and as monotherapy for BRCA1/2-mutated metastatic HER2-negative breast cancer. Petrovax Pharm will handle supply and localisation of the product.

Fuzuloparib belongs to the PARP inhibitor class — drugs that exploit synthetic lethality in tumours with defective DNA repair, particularly BRCA-mutated cancers — alongside olaparib, niraparib and rucaparib. The registration reflects Russia's push to widen domestic access to targeted oncology therapies. For pharmacy students, PARP inhibitors are a cornerstone topic in pharmacogenomics and personalised medicine: BRCA testing determines who benefits, linking diagnostics directly to drug selection.

Conclusion

From the NPPA's trade margin rationalisation and the Supreme Court's push against unethical marketing in India, to a major counterfeit-drug bust, and a wave of oncology approvals — Enhertu in China, atezolizumab and tucatinib at the FDA, and fuzuloparib in Russia — 9 October 2026 was dominated by cancer care and drug regulation. For pharmacy students, the day's news ties together the core pillars of the profession: drug pricing and patient access, marketing ethics, supply-chain integrity, targeted drug design, clinical trial interpretation, and pharmacovigilance. Learning to read approvals the way regulators write them — indication, trial, hazard ratio, safety warning — is one of the most practical skills a future pharmacist can build.

References

← All daily news